Myriad Genetics PT Raised to $28.00 (MYGN)
Investment analysts at Mizuho upped their price target on shares of Myriad Genetics (NASDAQ:MYGN) from $24.00 to $28.00 in a note issued to investors on Wednesday, Analyst Ratings Net reports. The firm currently has a “neutral” rating on the stock. Mizuho’s price target indicates a potential upside of 3.02% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Bank of America Corp. reiterated a “neutral” rating on shares of Myriad Genetics in a research note to investors on Tuesday, December 31st. They now have a $25.00 price target on the stock, down previously from $31.00. Separately, analysts at Goldman Sachs Group Inc. cut their price target on shares of Myriad Genetics from $32.00 to $20.00 in a research note to investors on Monday, December 30th. They now have a “hold” rating on the stock. Finally, analysts at Stephens cut their price target on shares of Myriad Genetics to $32.00 in a research note to investors on Monday, December 30th. They now have an “overweight” rating on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $27.27.
Myriad Genetics (NASDAQ:MYGN) traded up 0.04% during mid-day trading on Wednesday, hitting $27.43. The stock had a trading volume of 714,109 shares. Myriad Genetics has a one year low of $20.02 and a one year high of $38.27. The stock has a 50-day moving average of $24.05 and a 200-day moving average of $26.15. The company has a market cap of $2.050 billion and a price-to-earnings ratio of 13.13.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.66 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.46 by $0.20. The company had revenue of $204.06 million for the quarter, compared to the consensus estimate of $176.02 million. During the same quarter last year, the company posted $0.42 earnings per share. Myriad Genetics’s revenue was up 36.9% compared to the same quarter last year. On average, analysts predict that Myriad Genetics will post $1.97 earnings per share for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.